Linked Life Data

16007881

Source:http://linkedlifedata.com/resource/pubmed/id/16007881

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
66
pubmed:dateCreated
2005-7-12
pubmed:abstractText
Hodgkin's Lymphoma (HL) has developed to one of the best curable human cancers and overall about 80% of patients experience long-term disease free survival. Therefore, current treatment strategies aim at further improving treatment outcome, thereby trying to by minimize therapy-induced complications, such as infertility, cardiopulmonary toxicity, and secondary malignancies. Ongoing trials investigate a reduction of chemotherapy in terms of dose or cycles given, and the application of lower radiation doses and smaller radiation fields. For patients with a specific high-risk profile, new approaches with more intense drug combinations are currently being investigated. Moreover, the advent of effective salvage high-dose therapy for relapsed disease and a better understanding of prognostic factors have further improved the management of HL. Here, we summarize current strategies of the German Hodgkin Study Group (GHSG) in diagnostics and treatment of primary and relapsed HL, together with recent approaches for specific subgroups of HL patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Jul
pubmed:issn
0902-4506
pubmed:author
pubmed:issnType
Print
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
125-34
pubmed:dateRevised
2008-2-26
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Current treatment strategies of the German Hodgkin Study Group (GHSG).
pubmed:affiliation
Department I of Internal Medicine and German Hodgkin Study Group (GHSG), University Hospital Cologne, Cologne, Germany. beate.klimm@biometrie.uni-koeln.de
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't